🇺🇸 FDA
Pipeline program

EB-101

EB-101-CL-301

Phase 3 mab completed

Quick answer

EB-101 for Epidermolysis Bullosa is a Phase 3 program (mab) at ABEONA THERAPEUTICS INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
ABEONA THERAPEUTICS INC.
Indication
Epidermolysis Bullosa
Phase
Phase 3
Modality
mab
Status
completed

Clinical trials